American Association for the Advancement of Science, Science Translational Medicine, 471(10), 2018
DOI: 10.1126/scitranslmed.aau0417
Full text: Unavailable
Combining oncolytic virus and a MEK inhibitor augments immune-mediated therapeutic responses in melanoma and enhances sensitivity to PD-1 blockade in mice.